
    
      Patients receive indinavir bid plus ritonavir bid, plus 2 NRTIs bid (2 new NRTIs or 1 new
      NRTI and 1 NRTI without evidence of resistance). CD4 cell counts and plasma viral RNA are
      measured every 4 weeks for the duration of the study. Physical examination and laboratory
      tests of blood and urine are performed every 4 weeks for the duration of the study. Chest
      x-ray and 12-lead ECG are done prestudy.
    
  